[url="]Alnylam Pharmaceuticals, Inc[/url]. (Nasdaq: ALNY), the leading RNAi therapeutics company, to

CapsoVision, Inc. (CV) Q2 2026 Earnings Call Transcript

CapsoVision NASDAQ: CV reported second-quarter revenue growth as sales of its CapsoCam Plus capsule

CapsoVision (NASDAQ:CV) released second-quarter financial results and hosted an earnings call on Thu

CapsoVision, Inc.$250,000,000Common StockPreferred StockWarrantsRightsUnits    From time to time, we

SARATOGA, Calif., Aug. 13, 2026 (GLOBE NEWSWIRE) -- CapsoVision, Inc. (NASDAQ: CV), a commercial-sta

SARATOGA, Calif. , Aug. 03, 2026 (GLOBE NEWSWIRE) -- CapsoVision, Inc. (NASDAQ: CV), a commercial-st

SARATOGA, Calif., July 30, 2026 (GLOBE NEWSWIRE) -- CapsoVision, Inc. (NASDAQ: CV), a commercial-sta

SARATOGA, Calif., July 02, 2026 (GLOBE NEWSWIRE) -- CapsoVision, Inc. (Nasdaq: CV), a commercial-sta

AbbVie Receives Positive CHMP Opinion for Upadacitinib (RINVOQÂ) for the Treatment of Adults and Ado

AMGEN PRESENTS NEW DATA ACROSS ITS CARDIOMETABOLIC PORTFOLIO AT AMERICAN DIABETES ASSOCIATION 86TH S

U.S. stock futures were lower this morning, with the Nasdaq futures falling around 100 points on Mon

CapsoVision NASDAQ: CV reported steady first-quarter revenue and said it continues to advance artifi

CapsoVision, Inc. (CV) Q1 2026 Earnings Call Transcript

CapsoVision (NASDAQ:CV) reported quarterly losses of $(0.15) per share which missed the analyst cons

SARATOGA, Calif., May 14, 2026 (GLOBE NEWSWIRE) -- CapsoVision, Inc. (NASDAQ: CV), a commercial-stag

SARATOGA, Calif., April 30, 2026 (GLOBE NEWSWIRE) -- CapsoVision, Inc. (NASDAQ: CV), a commercial-st

CapsoVision (NASDAQ: CV - Get Free Report) and Nanovibronix (NASDAQ: FEED - Get Free Report) are bot

Benchmark analyst Bruce Jackson maintains CapsoVision (NASDAQ:CV) with a Speculative Buy and lowe

CapsoVision, Inc. (CV) Q4 2025 Earnings Call Transcript

CapsoVision (NASDAQ:CV) reported quarterly earnings of $0.02 per share which beat the analyst consen

CapsoVision, Inc. (the "Company") (NASDAQ: CV), a commercial-stage medical technology compan

Reports Preliminary, Unaudited Fourth-Quarter and Full Year 2025 Financial Results Reports Prelimina

SARATOGA, Calif., March 12, 2026 (GLOBE NEWSWIRE) -- CapsoVision, Inc. (NASDAQ: CV), a commercial-st

CapsoVision (NASDAQ: CV - Get Free Report) and Biosig Technologies (NASDAQ: STEX - Get Free Report)

CapsoVision, Inc. (NASDAQ: CV - Get Free Report) saw a large increase in short interest in the month

Benchmark analyst Bruce Jackson maintains CapsoVision (NASDAQ:CV) with a Speculative Buy and rais

U.S. stock futures mixed on Tuesday, potential stocks to watch: TEN Holdings up 17%, Fonar up 24%, C